Background
In the early 1970s I was a young radiotherapist/ oncologist at the Radiumhemmet, Karolinska Institutet, Stockholm -once a 'Mecca' for radiotherapy. Postoperative radiotherapy for breast cancer patients was routine there at that time. However, most breast cancer patients were dying of metastases and I questioned the effectiveness of routine use of local radiotherapy when so many patients were dying of disseminated cancer anyway. My peers in the hospital told me that 'their long clinical experience had shown them that radiotherapy was effective' and that it should be given routinely.
Undeterred, I reviewed and analysed the five published reports of controlled trials of local radiotherapy given after or before surgery. 1 None showed any survival benefit; indeed, compared to controls, mortality was higher in the irradiated groups in all of the trials. The increase ranged from 1% to 10%, between 1-10 years postoperatively. In two of the studies with data allowing an analysis by age and menstrual status, mortality after radiotherapy was about 15% higher in younger, premenopausal women.
I was never any good in mathematics and statistics but I know when and what I want them for. My Nordic 'bondförnuft' -literally, 'peasant sense'told me that although the higher mortality following radiotherapy seen in the trials was not statistically significant in the individual studies, taken together they might become statistically significant and that this might be demonstrated if there was a clever method of combining the data. I had published most of the articles from my PhD research in the Journal of the National Cancer Institute (JNCI) and that, together with The Lancet, were my favourite journals at that time. I remembered that I had seen an article in the JNCI in which data from several similar retrospective studies had been combined and analysed statistically. I therefore went to my statistical-epidemiological guru, Nick Day, at the International Agency for Research in Cancer, Lyon, and asked him if it could be done and, if so, if he could help. Nick immediately fished out the article by Mantel and Haenzel 2 and did the statistical analysis. In spite of my insistence, however, he declined to co-author my Lancet article with me. 1 So if my article is one of the earliest uses of meta-analysis of controlled trials in medicine, this is mainly thanks to Nick Day.
In the article I clearly acknowledged as already proven that radiotherapy reduced the risk of local and regional recurrences of breast cancer, but I questioned routine use of postoperative radiotherapy, over several weeks, to even node-negative breast cancer patients, given that the treatment seemed to be associated with increased mortality. Indeed, as early as 1959 a report of the first randomized trial of radiotherapy in breast cancer noted that 'Something seemed to be causing death shortly after treatment in a small number of patients who would not have died then had they not been irradiated'. 3
Reactions to the article
The article outraged the radiotherapy establishment, especially in North America, where radiotherapists felt that the evidence I had presented threatened not only their lucrative earnings but also their professional prestige. The latter was coming under threat from the rapidly emerging specialty of medical oncology, which had overtaken radiotherapy by developing and testing treatments for breast cancer with curative intent, and by demonstrating this in controlled trials with positive results (see, for example, Bonadonna et al. 4 ). As a result of my recent article, I found myself less frequently invited to radiotherapy meetings, but correspondingly more likely to be invited to cancer control and oncology meetings. An American surgeon, Bernard Fisher, was leading the largest breast cancer trials group in the world. Reflecting his own experience, he presented me with a hand-painted picture of a turtle with the legend 'Only by sticking out your neck do you advance'. He made me a member of his Turtle Club, and this helped me to weather the storm that followed my article.
A year after my article had been published, Levitt and McHugh 5 challenged my analysis, both in terms of the five clinical trials I had analysed, and my use of the Mantel-Haenszel technique to analyse them. In a rebuttal, 6 I and colleagues suggested that, in the absence of any suggested alternative statistical technique, it was appropriate to use the Mantel-Haenszel procedure, in spite of the technical differences between the radiotherapy regimens used in the five studies, again stressing that radiotherapy's reduction of local tumour recurrences was not in question. We stressed that therapeutic and economic priorities argued for a more critical approach to routine use of radiotherapy in early breast cancer, particularly as it seemed to be associated with increased mortality, an iatrogenic failure.
The following year, the same authors published two linked papers, one of which was entitled 'A re-examination of Stjernswärd's application of the Mantel-Haenszel statistical method'. 7 They suggested that there was no statistically significant evidence that survival was affected negatively by irradiation. I had not been invited to the American Cancer Society's National Conference on radiation oncology at which these papers had been presented, but Nick Day joined me in co-authoring a further rebuttal. 8 We pointed out that the authors had failed to refer to the earlier rebuttal, or to acknowledge that in every one of the trials included in my 1974 paper mortality was higher in the radiotherapy groups than in the control groups. Our use of the Mantel-Haenszel technique might have reduced the efficiency of the design of the analysis but would not have introduced bias. Given our findings, engaging in discussion of statistical niceties seemed to us to be displacement activity. I was invited to a breast cancer conference later the same year, organized under the aegis of the White House, the National Cancer Institute and the American Cancer Society, and I presented all the then available results from the relevant trials. 9 In an attempt to explain the higher death rate in women treated with radiotherapy by a decrease in immuno-competent cells after irradiation, I had speculated that an increase of metastasis due to a decreased immuno-competence might explain the increased number of deaths observed in the irradiated groups. This speculation proved wrong, however. Later data showed that the increased mortality could be explained by irradiation of the heart. [10] [11] [12] The development of more sophisticated meta-analyses
In the 1980s, resources were secured to allow a substantial development of my early metaanalysis. These were increasingly based on individual patient data, which allowed more detailed analyses (albeit still using the Mantel-Haenszel method!). In the first of these, published in 1987, 13 all trials that had matured were analysed, and this confirmed a statistically significantly higher mortality rate after 10 years in women who had received radiotherapy compared with controls. Most of these patients had participated in trials similar to those I had analysed in 1974. Orthovoltage irradiation had been used in these, and this damages the skin and the heart to a greater extent than subsequently adopted, more targeted, supervoltage irradiation. No statistically significant survival disadvantage was detected with these newer regimens. This was confirmed in a follow-up analysis published in the 1990s. This reported that 'the increased all-cause mortality rate in 10-year survivors previously reported is no longer [statistically] significant, although a numerical difference in favour of non-irradiated patients remains'. However, the authors also noted that 'an excess of cardiac deaths was apparent in both early and more recent trials'. 14 Analyses reported by the Early Breast Cancer Trialists' Collaborative Group 15 at the beginning of this century confirmed that local radiotherapy decreases local recurrences (8.8% vs. 27.2% 10 years post-treatment). Overall, they found a 20-year survival of 37.1% after radiotherapy compared with 35.9% survival among the un-irradiated control Journal of the Royal Society of Medicine patients. There was little difference in early mortality, but analyses of later deaths showed that radiotherapy reduced mortality rates from breast cancer but increased mortality from other causes. The report estimated that, if radiotherapy regimens without long-term hazards could be found, they might produce an increase in 20-year survival, except for women at particularly low risk of local recurrence. The confirmation of an increased mortality associated with irradiation prompts one to wonder, however, 15, 16 how many women with a low risk of local recurrence have died because of postoperative irradiation. More than 70% of the women in the analysis did not have any locoregional recurrences. 15
Conclusion
A meta-analysis of five trials of radiotherapy for breast cancer published nearly half a century ago identified a previously unrecognized hazard of this therapy, namely increased mortality. This prompted more detailed systematic reviews and meta-analyses confirming the effect and elucidating its cause, improved radiotherapy regimens to control local recurrence of the disease, and more careful selection of the women most likely to be helped by this local beneficial effect of radiotherapy. These advances in knowledge and practice were reflected in a recent editorial: 'it is a matter of some satisfaction that these early overviews have changed practice and we are now beginning to see the benefits of these improved protocols'. 17 An important challenge is to make progress in identifying those women who can be expected to benefit from radiotherapy and those for whom it may only present a life-threatening hazard. The identification of new risk markers may improve this discrimination, [18] [19] [20] but there will be a continuing need for systematic reviews and meta-analyses of well-designed studies addressing the possible differential effects of radiotherapy in newly identified subgroups.
A key ethical principle of good medical care is violated when patients are not told the truth about the effects of treatments, in terms that matter to them. Patients, clinicians and policymakers need ready access to valid systematic reviews of reliable evidence, with sufficient detail to support informed decision-making. Without these, patients will continue to suffer and die unnecessarily, and national resources for healthcare will often be wasted.
Thirty-four years after my article demonstrated harmful effects of the radiotherapy regimens in use at that time, the article is still being used for teaching at Harvard University. 21 Students are instructed to 'Use the sign test to show that Stjernswärd was actually correct in his conclusion'. This is encouraging evidence that some scientific approaches -albeit based on 'peasant sense' ('bondförnuft') -seem to stand the test of time.
